SecBot SecBot
SECBOTREPLAY Home › Report › INCY

INCY · Incyte announced a definitive agreement to acquire Vega Therapeutics (a…

INCYTE CORP · 8-K filed Jun 8, 2026 at 07:05 ET

At the news

BULLISHIMPACT 7/10

8-K filed Jun 8, 2026 at 07:05 ET

Incyte announced a definitive agreement to acquire Vega Therapeutics (a Star Therapeutics subsidiary) for $1.25 billion upfront, plus up to $750 million in sales milestones, totaling up to $2.0 billion. The deal adds VGA039, a Phase 3 monoclonal antibody for von Willebrand disease, to Incyte's hematology portfolio. The transaction is expected to close in Q3 2026, subject to HSR review, and will result in an ~$1.25 billion R&D charge.

  • Incyte to acquire Vega Therapeutics for $1.25 billion upfront, with up to $750 million in sales milestone payments (total potential consideration up to $2.0 billion).
  • VGA039 is a first-in-class, Phase 3 monoclonal antibody targeting Protein S for von Willebrand disease (VWD), with FDA Breakthrough Therapy, Fast Track, orphan drug, and rare pediatric disease designations.
  • VGA039 is already in the Phase 3 VIVID-6 study (NCT07115004), a global single-arm crossover study for all VWD types.
  • Transaction expected to close in Q3 2026, pending Hart-Scott-Rodino antitrust review.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access